In today’s briefing:
- L’Occitane (973 HK): Controlling Shareholder Mulling a Bid?
- LianLian DigiTech IPO: The Bull Case
- Black Sesame Pre-IPO – The Negatives – Losses Remain Wide and Suffers from a Concentration Risk
- CanSino Biologics (6185.HK/688185.CH) – The Story Has Changed
- Robosense Technology Pre-IPO – The Negatives – Not a Whole Lot of Earnings
- Morning Views Asia: China Vanke , Greenland Holdings Corp, Sino-Ocean Service
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
L’Occitane (973 HK): Controlling Shareholder Mulling a Bid?
- L’Occitane (973 HK) is drawing takeover interest from Reinold Geiger, the Chairman and the largest shareholder, according to Bloomberg. Mr Geiger has been exploring financing options for the potential deal.
- The presence of a significant disinterested shareholder, Acatis KVG, necessitates an attractive takeover premium. Acatis KVG trimmed its stake in July 2021 at HK$30.01 per share.
- L’Occitane released a solid 1QFY2024 update today with constant currency growth of 24.5% YoY. Irrespective of a bid materialising, the valuation is undemanding compared to peer multiples.
LianLian DigiTech IPO: The Bull Case
- Lianlian DigiTech (2104619D CH), a digital payment services provider in China, has filed for an HKEx IPO to raise US$500 million, according to press reports.
- Lianlian ranked first among the independent digital payment solution providers in China in terms of TPV in 2022, with a market share of 9.1%, according to Frost & Sullivan.
- The key elements of the bull case rest on rising market share, doubling of active customers, resilient core business growth and rapidly growing additional revenue streams.
Black Sesame Pre-IPO – The Negatives – Losses Remain Wide and Suffers from a Concentration Risk
- Black Sesame Technologies (BLACKSES HK) is looking to raise around US$300m in its upcoming Hong Kong IPO.
- Black Sesame International Holdings (BSIH) is an automotive-grade computing SoC and SoC-based intelligent vehicle solution provider.
- In this note, we will talk about the not so positive aspects of the deal.
CanSino Biologics (6185.HK/688185.CH) – The Story Has Changed
- Based on the current situation, sales of MCV4 in 2023 could still be unsatisfactory. We think MCV4 is hard to become the second growth curve of CanSino in post-COVID era.
- Whether CanSino’s zoster vaccine is able to become Best-In-Class would largely determine whether this product would truly become the next blockbuster vaccine to turn the situation around for CanSino.
- CanSino’s commercialized products cannot contribute large-scale revenue in time to prevent continuous deterioration of performance. Results in 2023 could be lower than expected, and investors are losing confidence in CanSino.
Robosense Technology Pre-IPO – The Negatives – Not a Whole Lot of Earnings
- Robosense Technology (ROBO HK) (RT) is looking to raise around US$400m (estimated) in its upcoming Hong Kong IPO.
- As of Mar 23, it had earned design wins for mass production of LiDAR for 52 vehicles with 21OEMs and Tier 1 suppliers, ranking No. 1 globally, according to CIC.
- In this note, we talk about the not-so-positive aspects of the deal.
Morning Views Asia: China Vanke , Greenland Holdings Corp, Sino-Ocean Service
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.